Claudio Sette Selected Research

RNA Splicing Factors

4/2022	Somatic Mutations in Core Spliceosome Components Promote Tumorigenesis and Generate an Exploitable Vulnerability in Human Cancer.
12/2019	Splicing Dysregulation as Oncogenic Driver and Passenger Factor in Brain Tumors.
1/2019	c-MYC empowers transcription and productive splicing of the oncogenic splicing factor Sam68 in cancer.
11/2018	The Splicing Factor PTBP1 Promotes Expression of Oncogenic Splice Variants and Predicts Poor Prognosis in Patients with Non-muscle-Invasive Bladder Cancer.
1/2017	EMT and stemness: flexible processes tuned by alternative splicing in development and cancer progression.
10/2015	SAM68 is a physiological regulator of SMN2 splicing in spinal muscular atrophy.
1/2015	The interplay between DNA damage response and RNA processing: the unexpected role of splicing factors as gatekeepers of genome stability.
3/2014	The centrosomal kinase NEK2 is a novel splicing factor kinase involved in cell survival.
7/2010	An emerging role for nuclear RNA-mediated responses to genotoxic stress.
1/2010	Alternative splicing of the cyclin D1 proto-oncogene is regulated by the RNA-binding protein Sam68.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Claudio Sette Research Topics

Disease

27	Neoplasms (Cancer) 05/2022 - 04/2004
9	Prostatic Neoplasms (Prostate Cancer) 05/2022 - 04/2004
5	Pancreatic Neoplasms (Pancreatic Cancer) 01/2021 - 01/2005
4	Adenocarcinoma 01/2021 - 01/2005
3	Autoimmune Diseases (Autoimmune Disease) 10/2015 - 01/2010
3	Carcinoma (Carcinomatosis) 05/2010 - 12/2008
2	Ewing Sarcoma (Sarcoma, Ewing) 01/2022 - 01/2019
2	Triple Negative Breast Neoplasms 01/2022 - 12/2021
2	Inflammation (Inflammations) 01/2021 - 07/2013
2	Multiple Sclerosis 01/2021 - 10/2015
2	Atrophy 01/2020 - 01/2018
2	Infections 01/2019 - 04/2010
1	Cardiomegaly (Heart Hypertrophy) 10/2022
1	Hypertrophy 10/2022
1	Hematologic Neoplasms (Hematological Malignancy) 04/2022
1	Ovarian Neoplasms (Ovarian Cancer) 03/2021
1	Neuroinflammatory Diseases 01/2021
1	Muscle Weakness 01/2020
1	Spinal Muscular Atrophy (Progressive Muscular Atrophy) 01/2020
1	Motor Neuron Disease (Primary Lateral Sclerosis) 01/2020
1	Brain Neoplasms (Brain Tumor) 12/2019
1	Necrosis 01/2019
1	Genetic Translocation (Chromosomal Translocation) 01/2019
1	Sarcoma (Soft Tissue Sarcoma) 01/2019
1	Non-Muscle Invasive Bladder Neoplasms 11/2018
1	Urinary Bladder Neoplasms (Bladder Cancer) 11/2018
1	Fibrosis (Cirrhosis) 01/2018
1	Muscular Atrophy (Muscle Atrophy) 01/2018
1	Neurodegenerative Diseases (Neurodegenerative Disease) 01/2017
1	Body Weight (Weight, Body) 10/2015
1	Experimental Autoimmune Encephalomyelitis (Encephalomyelitis, Autoimmune Experimental) 10/2015
1	Genomic Instability 01/2015
1	Neuroendocrine Tumors (Neuroendocrine Tumor) 04/2012
1	Azoospermia 04/2011
1	Male Infertility (Male Sterility) 12/2010
1	Carcinogenesis 05/2010
1	Seminoma 02/2009

Drug/Important Bio-Agent (IBA)

10	RNA Splicing FactorsIBA 04/2022 - 01/2010
10	Proteins (Proteins, Gene)FDA Link 01/2022 - 04/2004
10	RNA-Binding Proteins (RNA-Binding Protein)IBA 01/2021 - 04/2004
6	RNA (Ribonucleic Acid)IBA 01/2021 - 04/2009
5	Phosphotransferases (Kinase)IBA 01/2022 - 12/2008
4	Protein Isoforms (Isoforms)IBA 01/2017 - 01/2010
4	src-Family KinasesIBA 04/2012 - 04/2004
4	Messenger RNA (mRNA)IBA 07/2010 - 04/2004
3	Pharmaceutical PreparationsIBA 10/2022 - 01/2010
3	CyclinsIBA 01/2011 - 01/2010
2	RNA Helicases (RNA Helicase)IBA 05/2022 - 01/2019
2	DNA (Deoxyribonucleic Acid)IBA 05/2022 - 01/2015
2	Androgen Receptors (Androgen Receptor)IBA 05/2022 - 01/2011
2	RNA Precursors (Precursor, mRNA)IBA 11/2021 - 05/2017
2	Gemcitabine FDA Link 01/2021 - 04/2018
2	Cyclin D1IBA 01/2019 - 05/2010
2	CytokinesIBA 01/2019 - 07/2013
2	TOR Serine-Threonine KinasesIBA 10/2011 - 12/2008
1	Phenylephrine (Neo-Synephrine)FDA LinkGeneric 10/2022
1	Myosins (Myosin)IBA 10/2022
1	blebbistatinIBA 10/2022
1	Cyclin-Dependent Kinases (cdk Proteins)IBA 01/2021
1	Everolimus FDA Link 01/2021
1	Mechanistic Target of Rapamycin Complex 1IBA 01/2021
1	Immune Checkpoint InhibitorsIBA 01/2021
1	MTOR InhibitorsIBA 01/2021
1	NeurexinsIBA 01/2021
1	tilsotolimodIBA 01/2021
1	Histone Deacetylase InhibitorsIBA 01/2020
1	PanobinostatIBA 01/2020
1	Antisense OligonucleotidesIBA 01/2020
1	OligonucleotidesIBA 12/2019
1	EWS-FLI fusion proteinIBA 01/2019
1	Untranslated RNA (Noncoding RNA)IBA 01/2019
1	MicroRNAs (MicroRNA)IBA 01/2019
1	Interleukin-2 (IL2)IBA 01/2019
1	InterleukinsIBA 01/2019
1	Heterogeneous-Nuclear Ribonucleoproteins (Informatin)IBA 11/2018
1	130-nm albumin-bound paclitaxelIBA 04/2018
1	Interleukin-6 (Interleukin 6)IBA 01/2018
1	Pyruvate KinaseIBA 05/2017
1	Polypyrimidine Tract-Binding ProteinIBA 05/2017
1	p38 Mitogen-Activated Protein KinasesIBA 10/2015
1	ProteomeIBA 01/2015
1	Biological ProductsIBA 07/2013
1	Interleukin-1 (Interleukin 1)IBA 07/2013
1	Biomarkers (Surrogate Marker)IBA 01/2013
1	ElementsIBA 04/2011
1	Carrier Proteins (Binding Protein)IBA 04/2011
1	AndrogensIBA 01/2011
1	TriazolesIBA 01/2011
1	3- (2- ethylphenyl)- 5- (3- methoxyphenyl)- 1H- 1,2,4- triazoleIBA 01/2011
1	Toll-Like Receptor AgonistsIBA 06/2010
1	ChemokinesIBA 06/2010
1	NF-kappa B (NF-kB)IBA 06/2010
1	LigandsIBA 06/2010
1	A-factor (Streptomyces)IBA 05/2010
1	Heterogeneous Nuclear Ribonucleoprotein A1IBA 04/2010
1	Eukaryotic Initiation Factor-4EIBA 12/2008

Therapy/Procedure

5	Therapeutics 11/2021 - 03/2007
2	Drug Therapy (Chemotherapy) 11/2020 - 12/2016
1	Precision Medicine 03/2021
1	Denervation 01/2018